BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 26004431)

  • 1. SLC47A1 gene rs2289669 G>A variants enhance the glucose-lowering effect of metformin via delaying its excretion in Chinese type 2 diabetes patients.
    He R; Zhang D; Lu W; Zheng T; Wan L; Liu F; Jia W
    Diabetes Res Clin Pract; 2015 Jul; 109(1):57-63. PubMed ID: 26004431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphism of organic cation transporter 2 improves glucose-lowering effect of metformin via influencing its pharmacokinetics in Chinese type 2 diabetic patients.
    Hou W; Zhang D; Lu W; Zheng T; Wan L; Li Q; Bao Y; Liu F; Jia W
    Mol Diagn Ther; 2015 Feb; 19(1):25-33. PubMed ID: 25573751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential increments of basal glucagon-like-1 peptide concentration among SLC47A1 rs2289669 genotypes were associated with inter-individual variability in glycaemic response to metformin in Chinese people with newly diagnosed Type 2 diabetes.
    Liang H; Xu W; Zhou L; Yang W; Weng J
    Diabet Med; 2017 Jul; 34(7):987-992. PubMed ID: 28321905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of the SLC47A1 Gene Variant With Responses to Metformin Monotherapy in Drug-naive Patients With Type 2 Diabetes.
    Kim H; Bae S; Yoon HY; Yee J; Gwak HS
    J Clin Endocrinol Metab; 2022 Aug; 107(9):2684-2690. PubMed ID: 35639991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of effect of the SLC47A1 and SLC47A2 gene polymorphisms on the glycemic response to metformin in type 2 diabetes mellitus patients.
    Raj GM; Mathaiyan J; Wyawahare M; Priyadarshini R
    Drug Metab Pers Ther; 2018 Dec; 33(4):175-185. PubMed ID: 30433870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenomic association between a variant in SLC47A1 gene and therapeutic response to metformin in type 2 diabetes.
    Tkáč I; Klimčáková L; Javorský M; Fabianová M; Schroner Z; Hermanová H; Babjaková E; Tkáčová R
    Diabetes Obes Metab; 2013 Feb; 15(2):189-91. PubMed ID: 22882994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The MATE1 rs2289669 polymorphism affects the renal clearance of metformin following ranitidine treatment.
    Cho SK; Chung JY
    Int J Clin Pharmacol Ther; 2016 Apr; 54(4):253-62. PubMed ID: 26784938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of clinical and pharmacogenetic factors influencing metformin response in Type 2 diabetes mellitus.
    Pérez-Gómez N; Fernández-Ortega MD; Elizari-Roncal M; Santos-Mazo E; la Maza-Pereg L; Calvo S; Alcaraz R; Sanz-Solas A; Vinuesa R; Saiz-Rodríguez M
    Pharmacogenomics; 2023 Aug; 24(12):651-663. PubMed ID: 37610884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study.
    Becker ML; Visser LE; van Schaik RH; Hofman A; Uitterlinden AG; Stricker BH
    Diabetes; 2009 Mar; 58(3):745-9. PubMed ID: 19228809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic editing of metformin efficacy-associated genetic variants in SLC47A1 does not alter SLC47A1 expression.
    Kalamajski S; Huang M; Dalla-Riva J; Keller M; Dawed AY; Hansson O; Pearson ER; ; Mulder H; Franks PW
    Hum Mol Genet; 2022 Feb; 31(4):491-498. PubMed ID: 34505146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical pharmacokinetics of metformin.
    Graham GG; Punt J; Arora M; Day RO; Doogue MP; Duong JK; Furlong TJ; Greenfield JR; Greenup LC; Kirkpatrick CM; Ray JE; Timmins P; Williams KM
    Clin Pharmacokinet; 2011 Feb; 50(2):81-98. PubMed ID: 21241070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of
    Chen P; Cao Y; Chen S; Liu Z; Chen S; Guo Y
    Biomedicines; 2022 Oct; 10(10):. PubMed ID: 36289808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of metformin transporter gene SLC22A1 and SLC47A1 variants on steady-state pharmacokinetics and glycemic response.
    Ningrum VDA; Sadewa AH; Ikawati Z; Yuliwulandari R; Ikhsan MR; Fajriyah R
    PLoS One; 2022; 17(7):e0271410. PubMed ID: 35905099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Impacts of SLC22A1 rs594709 and SLC47A1 rs2289669 Polymorphisms on Metformin Therapeutic Efficacy in Chinese Type 2 Diabetes Patients.
    Xiao D; Guo Y; Li X; Yin JY; Zheng W; Qiu XW; Xiao L; Liu RR; Wang SY; Gong WJ; Zhou HH; Liu ZQ
    Int J Endocrinol; 2016; 2016():4350712. PubMed ID: 26977146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin.
    Stocker SL; Morrissey KM; Yee SW; Castro RA; Xu L; Dahlin A; Ramirez AH; Roden DM; Wilke RA; McCarty CA; Davis RL; Brett CM; Giacomini KM
    Clin Pharmacol Ther; 2013 Feb; 93(2):186-94. PubMed ID: 23267855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response.
    Becker ML; Visser LE; van Schaik RH; Hofman A; Uitterlinden AG; Stricker BH
    Pharmacogenet Genomics; 2010 Jan; 20(1):38-44. PubMed ID: 19898263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altered Glycemic Control Associated With Polymorphisms in the SLC22A1 (OCT1) Gene in a Mexican Population With Type 2 Diabetes Mellitus Treated With Metformin: A Cohort Study.
    Reséndiz-Abarca CA; Flores-Alfaro E; Suárez-Sánchez F; Cruz M; Valladares-Salgado A; Del Carmen Alarcón-Romero L; Vázquez-Moreno MA; Wacher-Rodarte NA; Gómez-Zamudio JH
    J Clin Pharmacol; 2019 Oct; 59(10):1384-1390. PubMed ID: 31012983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implication of critical pharmacokinetic gene variants on therapeutic response to metformin in Type 2 diabetes.
    Phani NM; Vohra M; Kakar A; Adhikari P; Nagri SK; D'Souza SC; Umakanth S; Satyamoorthy K; Rai PS
    Pharmacogenomics; 2018 Jul; 19(11):905-911. PubMed ID: 29914345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetic variation of
    Mousavi S; Kohan L; Yavarian M; Habib A
    Mol Biol Res Commun; 2017 Jun; 6(2):91-94. PubMed ID: 28775995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Protocol for the Study of Polymorphisms and Response to Metformin in Patients with Type 2 Diabetes in Trinidad.
    Clement Y; Singh S; Motilal S; Maharaj R; Nunez-Smith M
    Ethn Dis; 2020; 30(Suppl 1):211-216. PubMed ID: 32269463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.